TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

AI Briefing

• – TG Therapeutics announces completion of Phase 3 trial for BRIUMVI, evaluating subcutaneous dosing regimens every 2 months or every 3 months.
• – Phase 3 trial assesses efficacy and safety of BRIUMVI in various patient populations.
• – Results from the trial are expected to inform regulatory submissions and future clinical development.